Company Description
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally.
The company’s respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines.
It also provides oncology therapeutics, such as individualized neoantigen and checkpoint adaptive immune modulation therapy; and rare disease products, including propionic and methylmalonic acidemia, glycogen storage disease type 1a, ornithine transcarbamylase deficiency, phenylketonuria, crigler-najjar syndrome type 1, and cystic fibrosis.
It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Generation Bio Co.; immatics N.V.; Life Edit Therapeutics; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI.
The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018.
Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2010 |
| IPO Date | Dec 7, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 5,800 |
| CEO | Stéphane Bancel |
Contact Details
Address: 325 Binney Street Cambridge, Massachusetts 02142 United States | |
| Phone | 617 714 6500 |
| Website | modernatx.com |
Stock Details
| Ticker Symbol | MRNA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001682852 |
| CUSIP Number | 60770K107 |
| ISIN Number | US60770K1079 |
| Employer ID | 81-3467528 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Stéphane Bancel | Chief Executive Officer and Director |
| Dr. Stephen Hoge M.D. | President |
| James M. Mock | Chief Financial Officer |
| Shannon Thyme Klinger J.D. | Chief Legal Officer and Corporate Secretary |
| Dr. Jerh Collins Ph.D. | Chief Technical Operations and Quality Officer |
| Lavina Talukdar CFA | Senior Vice President and Head of Investor Relations |
| Tracey Franklin | Chief People and Digital Technology Officer |
| Dr. Melanie Ivarsson M.B.A., O.B.E., Ph.D. | Chief Development Officer |
| Dave Johnson | Chief Data and AI Officer |
| Dr. Charbel Haber M.P.H., Ph.D. | Senior Vice President and Head of Global Regulatory Science |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 1, 2025 | 10-Q | Quarterly Report |
| Aug 1, 2025 | 8-K | Current Report |
| Jun 11, 2025 | 144 | Filing |
| May 12, 2025 | SCHEDULE 13G | Filing |
| May 5, 2025 | 8-K | Current Report |
| May 1, 2025 | 10-Q | Quarterly Report |
| May 1, 2025 | 8-K | Current Report |
| Apr 30, 2025 | SCHEDULE 13G/A | Filing |
| Mar 11, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 11, 2025 | DEF 14A | Other definitive proxy statements |